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According to the global cancer incidence report, lung cancer is the most common malignancy and a leading cause 
of cancer-related death worldwide.1 In the USA, 
non-small-cell lung carcinoma (NSCLC) accounts 
for approximately 87% of all the cases of lung 
cancer with adenocarcinoma as the most prevalent 
subtype (40%).2 In Oman, NSCLC accounts for 88% 
of all lung cancers, with adenocarcinoma in 34% of 
cases, and squamous cell carcinoma (SCC) in 22%.3 
Despite diagnostic advances, lung cancer continues 
to present in advanced stages and as many as 50% of 
the patients have unresectable disease (stages IIIb–
IV), and perhaps an even higher percentage in the 
developing world [Table 1].2
Certain clinical parameters have an impact on 
the outcome of the disease. Gender affects outcomes 
as females generally are diagnosed at a younger age 
and earlier stage, and perhaps have an inherent 
greater longevity. Different races also have different 
5-year relative survival rates. In a study done 
between 2001–07, the 5-year survival rates were 
as follows: white men 13.7%; white women 18.3%; 
black men 11.6%; black women 14.5%.2 Weight loss, 
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العالج الفردي و املخصص لسرطان الرئة املنتشر من اخلاليا غري الصغرية
حممد فروخ، من�شور املنذري، فرحان خوجة زاهد، �شيام كومار، و اإكرام برين
اأن مر�شى املراحل املتقدمة  اأكدت موؤخرا  اآ�شيا واأوروبا  امللخ�ص: �شل�شلة من درا�شات املرحلة الثانية، واملرحلة الثالثة الع�شوائية يف 
من �رسطان الرئة من اخلاليا الغري �شغرية من النوع الفرعي الغدي الآوي لطفرات حمددة عندما تتعر�ض للعالج امل�شتهدف تظهر نتائج 
بقاء م�شاوية للذين عوجلوا بالعالج الكيميائي ومبناأى عن اإثارة الأعرا�ض اجلانبية. ان مفهوم العالج الكيميائي للجميع بداأ بالتال�شي، 
والو�شول للعالج الأمثل يربز كنقلة نوعية يف العالج. تو�شح هذه املقالة باإيجاز الآليات اخللوية امل�شاهمة يف �رسطنة الرئة و التي توفر 
اأ�شا�ض جزيئي للعالج امل�شتهدف. اإن التقدم يف علم الأحياء اجلزيئي ح�شنت فهمنا لالآليات التي ت�شارك يف مقاومة الأدوية البتدائية 
اأو الثانوية. يورد هذا املقال باإيجاز التطورات يف املوؤ�رسات احليوية ذات األأهمية التكهنية والتنبوؤية، واأثر البحوث املتعدية على نتائج 
العالج. اإن عالمة ما تعترب تكهنية اإذا توقعت النتائج، بغ�ض النظر عن العالج، وتنبوؤية اإذا توقعت نتائج عالج حمدد
الأوعية  بطانة  الب�رسة؛ عامل منو  الرئة؛ عامل منو  اخلبيثة يف  الأورام  الغري �شغرية؛  الرئة من اخلاليا  الكلمات: �رسطان؛ �رسطان  مفتاح 
الدموية؛ عالمات بيولوجية؛ مثبطات الربوتني كينيز.
abstract: A series of phase II and randomised phase III trials in Asia and Europe have confirmed recently 
that advanced stage non-small-cell lung carcinoma patients with adenocarcinoma subtypes harbouring specific 
mutations when subjected to targeted therapy experience equivalent survival outcomes as those treated with 
chemotherapy and are spared from its side effects. The concept of chemotherapy for all is fading, and therapy 
optimisation has emerged as a paradigm shift in treatment. This article briefly describes cellular mechanisms 
involved in lung carcinogenesis which provide a molecular basis for targeted therapy. Advances in molecular 
biology have improved our understanding of mechanisms involved in primary or secondary drug resistance. 
Evolving biomarkers of prognostic and predictive importance, and the impact of translational research on outcomes 
are also covered. A marker is considered prognostic if it predicts the outcome, regardless of the treatment, and 
predictive if it predicts the outcome of a specific therapy. 
Keywords: Carcinoma; Non-small-cell lung; Lung neoplasm; Receptor, Epidermal growth factor; Vascular 
endothelial growth factor; Biological markers; Protein kinase inhibitors, Bevacizumab, Erlotinib.
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poor performance status, advancing age, and the 
presence of concomitant illness may also adversely 
affect patient outcomes.4–7 Smoking has emerged as 
a prognostic and predictive marker. In addition, it 
also has certain significance, i.e. never smokers have 
epidermal growth factor receptor (EGFR) mutations 
at a rate of 37% compared to 14% in current and 
former smokers; k-ras mutations in 4% of never 
smokers as compared to 43% in current and former 
smokers, and echinoderm microtubule-associated 
protein-like4 anaplastic lymphoma kinase (EML4-
ALK) in 12% of never smokers as compared to 2% 
of current and former smokers. The prevalence of 
p53 mutation was the same in never smokers and 
current and former smokers (26% each).8 
Methods
Data were identified from searches of PubMed, 
Medscape, Google, and key cancer groups 
(American Society for Clinical Oncology, National 
Comprehensive Cancer Network, European Society 
for Medical Oncology) using search terms such as 
“chemotherapy in advanced NSCLC”, and various 
biomarkers of prognostic and predictive markers 
in lung cancer, EGFR, EGFR mutation (EGFRMUT), 
k-ras mutation, EML4-ALK mutation, MET, 
and T790M mutations. Reference was also made 
to key phase II and III trials and meta-analyses 
published in oncology journals including Chest, 
Clinical Advances in Hematology & Oncology, 
Journal of Clinical Oncology, New England Journal 
of Medicine, The Lancet Oncology, Oncologist, and 
Cancer. Information acquired from international 
scientific conferences was confirmed through 
computer searches.




Patients with advanced or metastatic NSCLC 
have traditionally been treated with systemic 
therapy if they carry a performance status of zero 
to two. Untreated, these patients have a median 
survival time of 3–4 months, and only one in 10 
patients survives 12 months on best supportive 
care (BSC).9–10 Cisplatin or carboplatin is the 
cytotoxic backbone when considering palliative 
chemotherapy.11 In 1995, a large meta-analysis 
revealed a 27% risk reduction in death and one 
year survival enhancement of 10% when comparing 
chemotherapy to best supportive care (BSC).12 
The Cochrane Collaboration Group upheld the 
advantage of platinum doublets which were 
associated with higher response rates (RR) and an 
absolute benefit of 5% improvement in one-year 
survival.13 
The Eastern Cooperative Oncology Group 
(ECOG) E1594 study is regarded as a reference 
trial of advanced NSCLC comparing four different 
chemotherapy regimens with each other (i.e. 
cisplatin combined in three arms with paclitaxel, 
gemcitabine, and docetaxel, respectively and 
the fourth arm comprising carboplatin and 
paclitaxel). The RR improved from 10 to 19%, and 
the median survival improved to 9.1 months for 
431 females, and 7.4 months for 726 males. The 
survival increased to approximately 33% in the 
first year and 11% in the second year. Essentially, 
all arms revealed similar median survival, but the 
regimen comprising cisplatin and gemcitabine was 
associated with longer time to progression (TTP), 
whereas carboplatin and paclitaxel was the least 
toxic amongst the four arms, and regarded as their 
reference doublet combination for future studies.10 
Other large phase III trials validated the results 
Table 1: Stage, distribution, and 5-year survival rate by 
stage at diagnosis: 2001–07 (Adapted from SEER2)









Distant (metastases) 56 <4
Not staged 07 08










* = Stage, distribution, and survival rate by stage of 43/52 patients with 
non-small-cell lung carcinoma at Sultan Qaboos University Hospital: 
2002–2011 (unpublished data); **NSCLC = non-small-cell lung 
carcinoma.
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By 2008, chemotherapy for NSCLC reached a 
plateau with median survival approaching 10–12 
months, while scientific research drifted towards 
molecular profiling with the evolution of cancer 
genetics and translational work. Researchers started 
to study the cell signalling pathways and evaluate 
means to target cancer cells at the molecular level. 
Others started to use maintenance therapy in their 
effort to enhance the median survival time in this 
aggressive disease.
Molecular Targets and 
Targeted Therapy in 
Metastatic NSCLC
tumour angiogenesis and 
vascular targets: bevacizumab
Vascular endothelial growth factor (VEGF) was 
discovered by Harold Dvorak and Donald Senger 
in 1983, and subsequently sequenced by Napoleone 
Ferrara's group in 1989.15,16 It was well-established 
that small tumours fail to thrive after attaining sizes 
as small as a few millimeters until they derive their 
independent vasculature. This in fact is carried out 
by the release of VEGF-A and other ligands that 
bind to the extracellular domain on the tumour 
cell VEGF receptors [Figure 1]. This initiates 
of the platinum doublets used in the E1594 trial 
and these doublets emerged as a standard of care 
for patients with well-preserved organ function 
in performance status (PS) 0–1, and with slightly 
higher toxicity in selected PS 2 cases.
Towards the end of the last decade, histology 
emerged as a strong predictor for response and 
enhanced survival in non-squamous NSCLC. 
Data from phase II and randomised phase III trials 
of patients having the adenocarcinoma subtype, 
including large cell carcinoma and bronchioalveolar 
carcinoma (BAC), confirmed improvement in 
median survival beyond 10 months after the 
addition of pemetrexed. A phase III study revealed 
survival approaching a statistically significant 
12.6 months in the pemetrexed cisplatin arm 
compared to 11 months in gemcitabine cisplatin 
arm in adenocarcinoma subtypes.14 The survival 
was 10.4 versus 6.7 months for the experimental 
arm in large cell carcinoma. SCC, however, did 
poorly with the addition of pemetrexed where 
median overall survival (OS) remained at <10 
months. The combination therefore emerged as 
an option for non-squamous subtypes, reaching a 
median survival time in excess of 12 months, while 
cisplatin plus gemcitabine or docetaxel remained 
the standard treatment for SCC. 
Figure 1: The EGFR and VEGFR cell signal transduction pathways and site of blockade by targeted therapies 1–3.
EGFR = epidermal growth factor receptor; TKI = tyrosine kinase inhibitor; VEGFR = vascular endothelial growth factor receptor; VEGF = 
vascular endothelial growth factor; mut = mutation.
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downstream cell signalling through activation 
of Ras/Raf/MEK/ERK or PI3K/Akt/mTOR 
pathways leading to cell proliferation, endothelial 
migration, angiogenesis, invasion, and metastases. 
The VEGF-A and platelet-derived growth factor 
(PDGF) binding to platelet-derived growth factor 
receptor (PDGFR) also complements the regulation 
of angiogenesis indirectly providing targets for 
dual- or multi-tyrosine kinase inhibitors (TKIs). 
Bevacizumab blocks the VEGF-A and prevents 
binding to the VEGF receptor while the complex is 
recognised and eliminated by the immune system. 
Bevacizumab exerts its action through the following 
proposed mechanisms. Antivascular effects lead 
to the regression of the tumour vasculature and 
reduce tumour size. Antiangiogenesis  inhibits 
neo-angiogenesis and recurrent blood vessel 
growth in the tumour. Antipermeability decreases 
vascular permeability, and oedema in the tumour 
microenvironment, reducing pleural fluid volume.
After promising results from a US phase II 
trial by Johnson et al. in 2004, a series of large 
randomised phase III trials of bevacizumab were 
initiated [Figure 2].17 A subset analysis of a phase 
III trial by Sandler et al. revealed interesting 
findings: patients with an adenocarcinoma 
subtype had a survival advantage of 3.9 months.18 
Additionally, patients who developed hypertension 
on bevacizumab had a superior OS.19 Also, elderly 
patients (>70 years) showed a trend of higher RR and 
(progression-free survival) PFS but no gains in OS. 
They also experienced more toxicity. The outcome 
of patients on maintenance bevacizumab showed 
promise on retrospective review and, therefore, 
a series of successful phase III maintenance trials 
were initiated to test its relevance. 
The addition of bevacizumab to pemetrexed 
and platinum improved survival outcomes 
in adenocarcinoma histology in two phase II 
trials.20,21 A randomised phase III maintenance trial 
(AVAPERL 1) in PS 0–1 advanced adenocarcinoma 
patients was initiated using pemetrexed-cisplatin 
plus bevacizumab followed by continuation 
bevacizumab with or without pemetrexed.22 The 
interim results seem promising, as the addition 
of bevacizumab was well tolerated and associated 
with a superior PFS of 3.6 months. The median OS 
for the bevacizumab arm was 15.7 months, but for 
the pemetrexed bevacizumab arm; an OS level has 
not yet been reached. The Pointbreak study (900 
patients) with advanced non-squamous NSCLC 
used pemetrexed + carboplatin + bevacizumab 
induction followed by pemetrexed + bevacizumab 
maintenance (arm A) and compared it with 
paclitaxel + carboplatin + bevacizumab induction 
followed by bevacizumab maintenance (arm B). 
Though it failed to reach the primary endpoint of 
enhancing OS, the maintenance arm A improved 
the survival outcomes (PFS and OS) compared to 
maintenance arm B.23 Whether the gain in survival 
is because of pemetrexed or bevacizumab remains 
to be defined. The ECOG E 5508 trial is underway 
to address this question.24 
In a meta-analysis of 2,252 patients from 5 
randomised trials with advanced NSCLC, Andre 
et al. reported that the addition of bevacizumab 
to platinum doublets increased RR, enhanced PFS 
by 1.4 months, extended OS by 1 month, and was 
associated with a significant 11% reduction in death. 
However, the combination was associated with 
slightly higher toxicity and mortality and therefore 
warrants careful patient selection.25
Based on promising survival gains from a 
colorectal study (BRITE),26 the ARIES trial27 in 
NSCLC, and another American retrospective 
analysis of non-squamous NSCLC,28 a large multi- 
institutional, randomised trial called Avastin 
in all Lung Lines (AVAll) was initiated and is 
currently recruiting patients to evaluate the role 
of post-progression bevacizumab.29 Nearly all 
key trials exploring the efficacy of the addition of 
bevacizumab to standard platinum doublets 
showed a consistent improvement in RR, PFS, and 
median survival rates in adenocarcinoma subtypes 
Figure 2: Continued survival benefit with bevacizumab: 
2006 to 2011 showing the major trials undertaken.
-The yellow bars show the subset analysis for ECOG4599 trial.
-The red bar is the control (chemotherapy arm) of ECOG 4599 
trial.
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epidermal growth factor 
receptor (egfr) 
EGFR is a trans-membrane cellular protein receptor 
located on the cell surface. The gene that codes for 
EGFR protein is located in 7p11-13. It consists 
of 26 exons, of which the first 14 code for the 
extracellular ligand binding domain, exon 15 for 
the transmembrane domain, and the last 11 for 
the intracellular domain. The ATP-binding site and 
intrinsic TK activity is also coded by exons 16–26.43 
It is generally expressed at low levels in a wide variety 
of normal tissues. Excessive expression or activation 
of EGFR is able to induce malignant transformation. 
Over-expression has been observed in 40–80% of 
NSCLC.44-46 A form of EGFRMUT (EGFRvIII) is 
implicated in carcinogenesis with TK activity.47
Receptor activation is generally initiated by 
the binding of EGF or related ligands, leading to 
receptor homodimerisation or heterodimerisation, 
which activates intrinsic TK activity of the receptors 
leading to autophosphorylation of tyrosine residues. 
Mutations or over-expression in the TK domain 
of the EGFR gene increase the activity of the 
intracellular signalling cascades through Ras/Raf/
MAPK and PI3K/Akt/mTOR pathways [Figure 1], 
leading to events which result in over-proliferation, 
differentiation, enhanced survival, inhibition of 
apoptosis, neo-angiogenesis, and metastases, and is 
associated with a poorer prognosis.48,49
Determination of EGFR gene mutations has 
clinical relevance as it allows the optimisation 
of therapy and has emerged as one of the most 
important single predictive molecular markers in 
clinical oncology. Patients with certain EGFRMUT 
derive significant benefit after the addition of 
gefitinib or erlotinib.50–52 These agents inhibit 
the TK and adversely compete with ATP for the 
critical ATP-binding site located in the intracellular 
domain inhibiting the intrinsic tyrosine kinase 
enzyme activity. Cetuximab is a monoclonal 
antibody that binds the extracellular domain of 
EGFR effectively and prevents the subsequent 
intracellular cascade of events and the inhibition of 
malignant transformation [Figure 1]. Certain clinical 
subgroups of patients derive a greater benefit from 
tyrosine kinase inhibitors (TKI) therapy by virtue of 
the presence of an EGFRMUT. These include patients 
of East Asian origin, never smokers, females, and 
those having an adenocarcinoma.53–54 The EGFRMUT 
are found in exons 18–21 of the EGFR gene.43 
with PS 0–1 [Figure 2]. However, the 4,000 patients 
(>65 years) from the SEER database were recently 
analysed and the addition of bevacizumab was not 
found to be advantageous in the elderly population.30 
When a single cellular target is blocked, the 
cancer cell finds an alternative pathway to proliferate 
and hence provides a rationale for dual or multi-
targeted therapy. Phase II and III trials, using dual 
TKI (vandetanib) after multi-line chemotherapy 
failure in advanced NSCLC, provided a hint of 
activity and efficacy in favour of the combination 
of chemotherapy with vandetanib.31–34 Multi-TKI 
(i.e. sorafenib, which inhibits TK, VEGFR, PDGFR, 
and the Raf signalling pathway when compared 
to a placebo) failed to enhance the efficacy of the 
treatment.35–36 In the MISSION trial, sorafenib 
failed to improve the OS, but the PFS, TTP, RR, and 
disease control rate (DCR) improved substantially.37 
BATTLE, a phase II study, incorporated heavily 
pretreated NSCLC patients with PS 0–2 (2–5 
lines failures, brain metastases allowed). The study 
compared the effects of erlotinib in the EGFR 
mutation-positive group, which validated results 
of earlier randomised trials, versus vandetanib and 
erlotinib, which showed enhanced activity in the 
VEGFR2-expressing subsets versus erlotinib and 
bexarotene showing activity in cyclin D1 expressing 
and EGFR amplified patients with improved 
outcomes versus. sorafenib which was associated 
with a dismal outcome in EGFR-mutation positive 
subsets.38,39 Multi-TKI roles in the metastatic 
setting remain under investigation. However, 
there is emerging data of multi-TKI use in RET 
translocations (1%) in adenocarcinoma subtype.
BIBF 1120, a triple angio-kinase inhibitor 
(active against FGFR, PDGFR, and VEGFR) in 
the second- or third-line setting was found to be 
associated with tumour shrinkage in patients with 
adenocarcinoma.40 Its use is being explored in 
combination with docetaxel and pemetrexed.41,42
With advances in molecular biology and genetics, 
newer markers of significance are being explored to 
determine their prognostic or predictive value, and 
non-squamous NSCLC has emerged as a classical 
model of studying cancer genetics. Discovery of 
key cellular markers and their targeting has started 
to bring a paradigm shift in the management of 
advanced adenocarcinoma subtypes and will be the 
focus of the following discussion.
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 TargeTing The epidermal growTh
 facTor recepTor (egfr) lung
The different types of EGFR mutations provide 
information on whether patients with these 
mutations are likely to benefit from TKIs (erlotinib 
or gefitinib)50–52,56 [Table 2]. An individual matching 
the clinical criteria above carries a 50% chance 
of harbouring the mutation, but this is not the 
sole criteria used to commence TKI therapy. 
EGFRMUT are present in 30–50% of East Asians and 
approximately 10% of Caucasians having NSCLC. 
Its exact incidence in Arabian Gulf countries 
or Oman is not known. Well to moderately 
differentiated tumours have more frequent EGFRMUT 
than their poorly differentiated counterparts.57 
Adenocarcinoma, which is thyroid transcription 
factor 1 (TTF1) negative, will usually harbour a 
wild-type (normal) EGFR (EGFRWT).
58,59
Around 30% of SCCs overexpress the EGFR 
protein (not the gene) on immune-staining, and 
TKI provides a similar advantage to this subtype. 
The evidence of adding a TKI in SCC comes from 
the subset analysis of the SATURN study and the 
exploratory retrospective analyses from the NCIC 
BR.21 trial according to which these agents enhance 
PFS and OS irrespective of histology when used 
as maintenance and second-line salvage therapy, 
respectively.60,61 Similarly, data from the FLEX 
trial recommend use of cetuximab with induction 
chemotherapy in SCC expressing the EGFR protein. 
EGFR mutations rarely occur in never smoking 
SCC patients, and therefore are not routinely 
determined.
 TargeTing The egfr inTracellular
 domain: Tyrosine kinase inhibiTors
 (Tkis)
After successful preclinical studies, evidence that 
the EGFRMUT correlated with response to TKI in 
clinical practice first emerged in 2004 from phase II 
trials in previously treated NSCLC patients. 
Trials of salvage TKIs have been undertaken. 
In the IDEAL 1 trial, gefitinib was used in 
patients pretreated with two or fewer previous 
chemotherapy regimens, while in IDEAL 2 the 
same agent was used in pretreated NSCLC patients 
who received more than two regimens.62,63 In 210 
patients, the RR were 18–19% and there were 
median survival gains of 7.6–8 months in the 
IDEAL 1 trial. The RR was 11.8% and median OS 
was 6.5 months in the IDEAL 2 trial. The subset 
analyses revealed that Asian, never smoking 
females having adenocarcinoma (especially BAC) 
reacted with a predictable response to gefitinib. 
The ISEL, a phase III study, used gefitinib as first 
salvage in NSCLC after one or more prior 
chemotherapy failures. Survival was increased 
in patients who were Asians or never smokers.53 
INTEREST, a phase III trial, utilised gefitinib versus 
docetaxel in a second-line salvage setting. The TKI 
was associated with a superior quality of life (QoL) 
and fewer side effects.64 Erlotinib was also used 
as a monotherapy in patients with NSCLC who 
progressed on 1–2 previous chemotherapies in the 
phase III BR.21 trial against BSC, and was associated 
with improvement in disease-related symptoms, 
superior TTP, and median OS enhancement by 2 
months.61  
Phase III trials of concurrent use of TKIs with 
chemotherapy have also been conducted. TALENT 
was a negative trial (>1,172 patients) with two 
arms that used carboplatin and paclitaxel with or 
without erlotinib.65 The RR, PFS, and OS remained 
unchanged when the TKI was used concurrent 
with chemotherapy as compared to chemotherapy 
alone. The TRIBUTE study utilised cisplatin and 
gemcitabine alone or concurrent with erlotinib and 
validated the results of the TALENT trial.66 However, 
subset analyses revealed increased survival in never 
smokers. INTACT 1 and INTACT 2 also used 
carboplatin and paclitaxel alone or concurrent 
Table 2: Epidermal growth factor receptor mutation types, incidence, and sensitivity to tyrosine kinase inhibitors
Sr. No. EGFR mutation type Known mutations % Sensitivity to TKI
1 Exon 19 del(del 746-A750)




2 Dual mutationsT790M/exon19del T790M/L858R/others 5–7 ? No, data limited





EGFR = epidermal growth factor receptor; TKI = tyrosine kinase inhibitor.
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The OPTIMAL trial was conducted by the 
Chinese Thoracic Oncology Group, and involved 
23 centres using erlotinib.51,52 The trial also validated 
results from the IPASS study. In subgroup analyses, 
PFS was 15.3 months in exon 19 del and 12.5 
months in L585R mutation. Table 3 shows the key 
phase III, prospective randomised clinical trials of 
upfront TKIs in non-squamous NSCLC with almost 
similar outcomes.50–52,55,72–74 At disease progression 
on TKIs, patients may still be treated with salvage 
platinum doublets. 
The TORCH trial revealed that in unselected 
advanced NSCLC patients, first-line erlotinib 
(followed by cisplatin gemcitabine at progression) 
was inferior in terms of OS compared with the 
standard sequence of first-line chemotherapy 
followed by erlotinib at progression.75 TAILOR is 
another phase III trial, where 218 evaluable patients 
(EGFRWT) were subjected to second-line docetaxel 
or erlotinib. The PFS was superior in the docetaxel 
arm with an absolute difference in 6 months PFS 
of 12% and remains a negative trial for TKI in wild 
type EGFR.76
 TargeTing The egfr exTracellular
domain: ceTuximab
After encouraging results from phase II trials of the 
addition of cetuximab to induction chemotherapy 
in metastatic NSCLC, phase III trials were 
initiated. The monoclonal antibody binds to the 
extracellular ligand binding domain of the EGFR, 
blocking the intracellular cell signalling [Figure 
1]. FLEX (First Line Erbitux in Lung Cancer trial) 
is a key phase III, randomised trial comparing the 
addition of cetuximab to cisplatin and vinorelbine, 
given for 6 cycles and cetuximab continued as 
maintenance therapy until progression of disease 
or unacceptable toxicity versus chemotherapy 
alone. The median OS was superior.77 Moreover, a 
high EGFR expression was associated with a better 
survival with the addition of cetuximab. Survival 
figures were also superior for females, those of 
Asian ethnicity, in those who developed acne, and 
in those having adenocarcinoma. The addition of 
cetuximab to chemotherapy was found to be as 
effective in SCC with a prolongation of one year 
survival by 19%.78 Another USA-based trial looked 
at unselected NSCLC patients treated with taxane 
plus cetuximab, which enhanced median OS.79 The 
addition of cetuximab to platinum doublets remains 
a reasonable option in distinct PS 0–1 patients, as 
erlotinib without improvement in efficacy.67,68 
CALGB 30406, presented in ASCO 2012, reveals 
erlotinib efficacy as singlet or concurrent with 
paclitaxel carboplatin in never or light smokers, 
harboring adenocarcinoma. Erlotinib was found 
to have similar efficacy in EGFRMUT in this phase 
II setting whether used as a singlet, and with 
higher toxicity or when used in combination with 
chemotherapy.69 There is a hint of TKI continuation 
concurrent with chemotherapy in some NSCLC 
cases associated with flare-up of the disease on 
discontinuation of the TKI. TKI use concurrent 
with chemotherapy remains investigational and 
necessitates further study in the context of a phase 
III trials.
Trials comparing TKIs to chemotherapy 
as initial therapy have also been carried out. 
When TKI was used as frontline therapy in 
adenocarcinoma harbouring the EGFRMUT, the RR 
and PFS improved substantially but with similar OS 
gains to those seen with chemotherapy.50–52,56,70–74 
Similar efficacy, superior tolerability, and less 
toxicity made TKI a new therapeutic option for 
adenocarcinoma subtypes, as well as its potential 
use in PS 3 and selected PS 4 cases. Certain 
clinical subgroups of patients with an EGFRMUT 
had a substantial enhancement in median survival, 
including those having an adenocarcinoma, 
never smokers, females, ethnic Asians, and those 
who developed a high-grade, acne-like rash with 
TKI.64–68,70–74 
In the Iressa Pan-Asia Study (IPASS), a phase 
III, multicentre, randomised trial of advanced 
NSCLC, 1,217 patients from East Asia were 
randomly assigned to receive daily TKI orally versus 
a platinum doublet every 3 weeks for 6 cycles.50 
Crossover was allowed. One-third of the patients 
had an EGFRMUT. The objective RR was statistically 
and numerically superior in the gefitinib arm in all 
clinical subgroups, with marked improvement of 
RR in the EGFRMUT-positive subgroup. However, 
the median OS remained similar, and mutation-
negative patients benefited from chemotherapy but 
did extremely poorly with gefitinib (RR = 1%). The 
TKI are therefore not indicated in EGFRWT. The 
OS was similar in the EGFRMUT positive or negative 
groups and is possibly due to crossover in the two 
arms. The survival was also superior in patients 
with a high EGFR gene copy number, however, at 
the expense of mild toxicity. 
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shown in the algorithm in Figure 3. It is reasonable 
to consider adding cetuximab to platinum doublets 
in patients with SCC (30% of these express the 
EGFR protein) and then use it as maintenance in 
those stablising after induction therapy, where it 
adds 1 month to OS.
Molecular Markers of 
Significance in Targeted 
Therapy
With advances in molecular biology and 
translational research, molecular targets are 
evolving which are potential targets of newer drugs 
[Tables 3 and 4]. Some key markers of prognostic 
and predictive value are described below.
met amplification
MET is a cell surface receptor with TK activity 
expressed by normal cells as well as malignant 
cells.80 It is amplified in 10–20% of NSCLC. 
Ligand-like hepatocyte growth factor/scatter 
factor binds to MET, activating downstream 
cell signalling and leading to cell proliferation, 
angiogenesis, invasion and metastases. High 
expression is defined on immunostaining, when 
>50% cells stain strongly (>3+) or, by an increased 
gene copy number (>5 copies/cell) as detected by 
fluorescent in situ hybridisation (FISH). MET and 
EGFR coamplification occurs rarely—in only 1% of 
cases. The incidence of MET mutation was highest 
in Asians (13%), 0% in blacks, and N375S was the 
commonest mutation.81 MET amplification may 
lead to acquired resistance to TKI therapy through 
activation of alternate cell signalling pathways like 
PI3K in up to 20% of patients.82,83 It is also associated 
with reduced TTP. The PFS varies inversely with 
MET overexpression. Patients with high MET had 
superior survival with chemotherapy (P 0.25). Several 
MET inhibitors, with or without dual inhibition 
of EGFR and MET as a potential mechanism to 
overcome resistance, are currently undergoing 
trials. MET inhibitors like METMab plus erlotinib 
versus placebo plus erlotinib were compared in a 
phase II trial and showed 50% enhancement in PFS 
and OS in patients with high MET expression.84 
Patients with low MET expression fared worse 
with the same combination. ARQ 197 is another 
MEK inhibitor that showed superior PFS when 
combined with erlotinib in a phase II trial with a 
trend towards increased OS.85 The MetLung trial 
is a global phase III randomised trial recruiting 
patients with metastatic or recurrent disease after 
one previous chemotherapy failure in MET-positive 
NSCLC. Patients are being randomised to erlotinib 
plus onartuzumab (MetMab) versus erlotinib plus 
placebo.86  
k-ras mutation
Mutations in the Kirsten rat sarcoma virus oncogene 
homologue gene (k-ras) occurs in approximately 
20–30% of NSCLC cases. They are common in 
mucinous adenocarcinoma (but not in large-cell 
carcinoma or BAC), in the elderly, in heavy smokers, 
in stage I and tumour grade I but frequently fall 
with stage and grade progression, while the 
Table 3: Phase III, prospective, randomised clinical trials of upfront tyrosine kinase inhibitor- erlotinib (E), and 
gefitinib (G)
Study No. of 
Patients






tKI trials EGFrMUt P value NS
IPASS50(G) China 261; 132 71.2 91.7 9.8 vs. 6.4 21.3 vs. 23.3 0.48
OPTIMAL51,52(E) Asia 154; 82 82.9 96.3 13.7 vs. 4.6 18.8 vs. 17.4 0.16
EURTAC56(E) Europe 1275; 174 54.5 10.5 10.4 vs. 5.1 22.9 vs. 18.8 0.34
First-SIGNAL70(G) Korea 42; 26 84.6 88.5 8.4 vs. 6.7 21.3 vs. 23.3 0.613 
NEJSG 00271(G) Japan 228; 114 73.7 89.5 10.8 vs. 5.4 30.5 vs. 23.6 0.30 
WJTOG 340572(G) Japan 172; 86 62.1 93.1 9.2 vs. 6.3 36.3 vs. 39 0.489
SLCG73(E) Spain 217; 217 70.6 89.8 14.0 27 --
CALGB 3040669(E) US 181; 164 71 NR 14.1 vs. 2.6 OS 31 vs.18
ORR = objective response rate; DCR = disease control rate; PFS = progression free survival; OS = overall survival; HR = hazard ratio; TKI = tyrosine 
kinase inhibitor; EGFRMUT = epidermal growth factor mutation; NS = not significant; NR = not reported.
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only rules out EGFR mutation, but is also a marker 
of TKI inactivity. To date, patients harbouring the 
k-ras mutation are best treated with chemotherapy. 
In a recent trial comparing docetaxel with or without 
selumetinib (MEK 1 and 2 inhibitor downstream of 
k-ras), the combination resulted in superior RR, 
PFS, and OS in patients with the k-ras mutation.87
echinoderm microtubule-
associated protein-like4 
anaplastic lymphoma kinase 
(eml4-alk) mutation
EML4-ALK was isolated from a surgically resected 
lung adenocarcioma specimen, but originally 
identified in anaplastic large-cell lymphoma 
(ALCL).88,89 It occurs in 4–11% of NSCLC. EML4-
ALK exhibits activating mutations or translocations 
of the anaplastic lymphoma kinase aberrant 
fusion gene (result of a small inversion within 
short arm of chromosome 2p, in which the EML4 
becomes fused to the intracellular kinase domain 
of ALK). It leads to the activation of downstream 
cell signalling through PI3K and STAT pathways. 
The gene encodes a cytoplasmic chimeric protein 
with kinase activity, and typically tested positive 
in younger subjects, having adenocarcinoma of a 
predominantly signet ring subtype, and in never or 
occurrence in non-smokers is low. The majority 
of mutations occur in codon 12 (>90%—guanine 
to thymine transversion) and 13, and the gene 
leads to impaired GTPase activity, located towards 
the inner surface of the cell membrane. This leads 
to subsequent constitutive activation of RAS 
signalling, which is downstream of the EGFR, 
leading to activation of proliferative and anti-
apoptotic pathways such as ERK. In the early 1990s, 
it was considered a negative prognostic marker, and 
perhaps a negative predictive marker responsible 
for chemo-resistance. However, data from recent 
trials like TRIBUTE and FLEX negates it.66,77 
Unlike colorectal cancers, where k-ras mutation 
is a strong predictor of response to cetuximab, 
its status in NSCLC could not confirm it to be so 
on retrospective analyses of FLEX and BMS 099 
trials.77,79
In the NCIC BR.21 study, 28% of 731 patients had 
k-ras genotype.61 The majority was wild type that 
responded well to TKI, while 15% had a mutation 
that conferred primary resistance to TKI therapy. 
Data from TRIBUTE reveals that EGFR and k-ras 
mutations rarely occur together, and that survival 
was inferior in the group of patients with k-ras 
mutation who were treated with chemotherapy plus 
TKI.66 Hence, the presence of k-ras mutation not 
Figure 3: Evolving treatment algorithm of non-small-cell lung carcinoma in 2012.
NSCLC = non-small-cell lung carcinoma; EGFR = epidermal growth factor receptor; CA = carcinoma; BAC = bronchioalveolar carcinoma; 
IHC = immunohistochemistry; VEGF = vascular endothelial growth factor; EML4-ALK = echinoderm microtubule-associated protein-like4 
anaplastic lymphoma kinase; PS = performance status; *BSC = best supportive care.
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light smokers who did not harbour EGFR mutations. 
Immunohistochemistry (IHC) could detect the 
protein, and reverse transcription polymerase chain 
reaction (RT-PCR), gene sequencing, and FISH 
could detect the break-apart rearrangement.90 The 
break removes the inhibitory effect of EML4 and 
ALK initiates carcinogenesis due to its inherent 
oncogenic activity. EML4-ALK positivity mutually 
rules out EGFR and k-ras mutations.
Currently, patients with this distinct expression 
have a similar RR and OS to platinum-based 
chemotherapy compared to the wild type patients. 
Crizotinib, an oral ALK inhibitor which produced 
a 90% clinical benefit (57% objective response rate 
[ORR]) when used as a second-line compared 
favourably to salvage second-line chemotherapy 
which produced a RR of 10% in a phase II trial.91 
Another phase II trial (PROFILE 1005) is assessing 
salvage crizotinib in adenocarcinoma patients 
treated with one previous platinum, with the 
finding that the ORRs were 54% and the DCRs were 
74%, which was considered safe and tolerable.92 
Recently, PROFILE 1007 data were presented to 
the European Society for Medical Oncology. ALK-
positive patients who failed one previous platinum 
doublet were treated with crizotinib compared 
with chemotherapy (docetaxel or pemetrexed). 
Crizotinib enhanced PFS (7.7 versus 3 months; 
P <0.0001), RR (60% versus 20%; P <0.001), and 
QoL.93 The exact sequencing of the drug still needs 
to be defined. Currently all patients harbouring wild 
type EGFR are treated with chemotherapy doublets 
and crizotinib is reserved as salvage in those who 
have the EML4-ALK mutation. The new agent 
is being tested in metastatic setting as frontline 
treatment. Crizotinib has also been found effective 
against ROS1 (~1%) mutation in NSCLC.
resistance to epidermal growth 
factor receptor (egfr) tyrosine 
kinase inhibitors (tkis)
At some point during the course of disease, 
NSCLC progresses, despite therapy, because of 
the emergence of resistance due to underlying 
Table 4: Personalised therapy in 2012 for non-small cell lung carcinoma
Factors Featurers/ Molecular Targets Targeted Therapy/Chemotherapy Options
Clinical Female, Never smoker, Asian, Adenocarcinoma 
Treated CNS metastases, No hemoptysis, Controlled 
hypertension, No tumor near great vessels, No VTE, 
No therapeutic anticoagulant therapy
TKI
Bevacizumab
Histologic Non mucinous Adenocarcinoma(EGFR Mutation+)
Mucinous adenocarcinoma(k ras mutation/ EGFR wild)
Mucinous adenocarcinoma(EML4 ALK+)
Nonsquamous subtypes
Squamous(30% EGFR protein expression)
TKI
Platinum doublets (pemetrexed)
Crizotinib 1st line or after induc chemo
Pemetrexed/ Cisplatin/ or both
Bevacizumab, Pemetrexed + Platinum
Gemcitabine or taxanes + Platinum + Cetuximab




EGFR Mutation + (FISH)
k ras +ive , EGFR wild type
EGFR overexpression on (for SCC)
cMET mutation
T790M mutation





Chemotherapy, (?ARQ 197, METMab)
Afatinib, (?AEE788+Everolimus)
Crizotinib
Pemetrexed/ Cisplatin/ or both
?Multi-TKI (Sorafenib/ Sunitinib)
Unanswered Triple negative lung cancer*(EGFR-, k ras -, EML4 ALK-)
 
Primary vs Metastases
Do poorly with standard chemotherapy, Best 
regimen?








Gemcitabine Docetaxel (cisplatin resistance)
Non-gemcitabine doublets (gemcitabine resist)
Non taxane combination (taxane resistance)
* = Retrospective subgroup analyse; ** = Markers undergoing research; CNS = central nervous system; VTE = venous thromboembolism; TKI = 
tyrosine-kinase; EGFR = epidermal growth factor reactor; FISH = fluorescence in situ hybridization; SCC = squamous cell carcinoma; EML4 ALK = 
echinoderm microtubule-associated protein-like4 anaplastic lymphoma kinase; ERCC1 = excision repair cross-complementation group 1; RRM1 = 
ribonucleotide reductase M1 gene inhibitor.
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30% of acquired resistance.101 It has also been shown 
that patients who have developed resistance to TKI, 
when subjected to chemotherapy, may respond 
again to the re-introduction of TKI.102 
Conclusion
Bevacizumab and cetuximab have emerged as 
targeted agents to be used with cisplatin doublets 
in metastatic adenocarcinoma in patients with 
PS 0–1 and well preserved organ function. Those 
harbouring the EGFRMUT in PS 0–3 and highly 
selected PS 4 are now candidates for oral TKI 
therapy which offers equal efficacy, superior 
tolerability, and a lesser and different side effect 
profile, bringing a paradigm shift in the management 
of these cancers. There are compelling data for 
using more or prolonged therapy, and optimising 
therapy based on histology and genetic mutations, 
while resistance patterns continue to be recognised. 
The era of one chemotherapy that fits all is fading 
as patients’ median survival is improving gradually 
under customised individualised therapy. 
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